Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionPENNX - Royce Pennsylvania Mutual Fund Investment Class
Latest Disclosed Ownership581,227 shares
Latest Disclosed Value $ 14,391,180
PENNX - Royce Pennsylvania Mutual Fund Investment Class reports 12.38% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 21, 2026 - PENNX - Royce Pennsylvania Mutual Fund Investment Class filed a NPORT-P form disclosing ownership of 581,227 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $14,391,181 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 12, 2026 disclosing 517,192 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 12.38% during the quarter. The current value of the position is $18,302,838 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-21 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 581,227 64,035 12.38 14,391 19.22 0.7916
2026-02-12 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 517,192 -6,288 -1.20 12,071 17.06 0.6808
2025-11-18 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 523,480 124,180 31.10 10,313 19.02 0.5721
2025-08-15 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 399,300 -12,169 -2.96 8,665 -13.17 0.5028
2025-05-19 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 411,469 -60,467 -12.81 9,978 1.31 0.6148
2025-02-21 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 471,936 -31,165 -6.19 9,849 -1.52 0.5265
2024-11-19 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 503,101 -88,591 -14.97 10,002 9.12 0.5082
2024-08-12 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 591,692 20,114 3.52 9,165 0.60 0.4822
2024-05-20 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 571,578 38,399 7.20 9,111 1.65 0.4651
2024-02-20 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 533,179 61,790 13.11 8,963 62.65 0.4798
2023-11-22 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 471,389 228,742 94.27 5,511 68.97 0.3299
2023-08-09 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 242,647 79,500 48.73 3,261 20.60 0.1871
2023-05-19 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 163,147 5,500 3.49 2,705 -7.78 0.1628
2023-02-21 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 157,647 58,100 58.36 2,932 129.60 0.1870
2022-11-17 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 99,547 -341,300 -77.42 1,277 -58.67 0.0858
2022-08-16 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 440,847 -67,700 -13.31 3,090 -26.69 0.1949
2022-05-16 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 508,547 -96,800 -15.99 4,216 2.86 0.2202
2022-02-24 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 605,347 -161,770 -21.09 4,098 0.81 0.1905
2021-11-22 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 767,117 -36,400 -4.53 4,066 -12.01 0.1919
2021-08-24 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 803,517 8,621 1.08 4,620 26.09 0.2012
2021-05-17 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 794,896 794,896 3,664 0.1625
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.